Telik announces patents on TELINTRA compounds

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Jun 11 2008

Telik, Inc. announced today that the European Patent Office has issued notices of allowance for two applications covering new compounds related to one of Telik's lead clinical candidates, TELINTRA.

Corresponding applications have already issued as patents in the United States; and other applications are pending in major countries worldwide.

TELINTRA is currently in Phase 2 clinical trials for the treatment of Myelodysplastic Syndrome, a form of pre-leukemia, and for Chemotherapy Induced Neutropenia, a common side effect of chemotherapy. Telik expects these applications and patents to provide broad intellectual property protection to compounds related to TELINTRA, according to Derek Freyberg, Ph.D., Telik's VP, Intellectual Property. The patents will help to broaden and strengthen Telik's intellectual property estate and may support additional clinical development candidates.

Source:

http://www.telik.com/

Posted in: Medical Patent News

Tags: , ,

Comments (0)

Suggested Reading

Quest Pharm and Aston University develop world-first tablet to treat mouth ulcerations in chemotherapy patients
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels
Researchers find new clue to treating aggressive Wilms tumor subtype
Study provides a hopeful direction for the management of penile squamous cell carcinoma
Innovative tool could safeguard cancer patients from chemotherapy-induced kidney damage
ACE inhibitors show no benefit in reducing chemotherapy-induced heart damage
Researchers develop a risk prediction model for cisplatin-induced kidney damage
Optimizing chemotherapy for older adults with advanced cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Neoadjuvant chemotherapy shows promise for advanced penile cancer